SAVA Stock Overview
A clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Revenue is forecast to grow 25.99% per year
Risk Analysis
Earnings are forecast to decline by an average of 30.3% per year for the next 3 years
Makes less than USD$1m in revenue ($0)
Highly volatile share price over the past 3 months compared to the US market
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Cassava Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.05 |
| 52 Week High | US$42.20 |
| 52 Week Low | US$8.79 |
| Beta | -0.63 |
| 11 Month Change | -3.20% |
| 3 Month Change | 133.42% |
| 1 Year Change | 34.63% |
| 33 Year Change | -49.79% |
| 5 Year Change | 1,951.18% |
| Change since IPO | -82.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| SAVA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.0% | -0.5% | -0.7% |
| 1Y | 34.6% | 18.5% | 30.3% |
Return vs Industry: SAVA exceeded the US Pharmaceuticals industry which returned 18.5% over the past year.
Return vs Market: SAVA exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| SAVA volatility | |
|---|---|
| SAVA Average Weekly Movement | 22.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SAVA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SAVA's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 29 | Rick Barry | www.cassavasciences.com |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. Fundamentals Summary
| SAVA fundamental statistics | |
|---|---|
| Market cap | US$1.22b |
| Earnings (TTM) | -US$15.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio
-81.3x
P/E Ratio
Is SAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAVA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$90.59m |
| Gross Profit | -US$90.59m |
| Other Expenses | -US$75.21m |
| Earnings | -US$15.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SAVA perform over the long term?
See historical performance and comparison